Eleven Biotherapeutics Company Profile

News Articles [ 260 Associated News Articles listed on BioPortfolio]

Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (...

Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, ...

Follows Successful Completion of Phase 1a Clinical Study Lead Candidate from Eleven’s AMP-Rx Product Engine for First-of-a-Kind Protein Therapeutics

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for E...

Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical ...

Results in Proceedings of the National Academy of Sciences Highlight the Beneficial Effects of EBI-005 Rationally-designed to Target and Block IL-1 for Ocular Inflammation

Data on novel IL-1 inhibitor protein for topical treatment of dry eye disease published

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences s...

Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that thre...

Smith & Nephew acquires Healthpoint Biotherapeutics for $782 million

Smith & Nephew has signed an agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash. Healthpoint Biotherapeutics has been focused on biopharma...

Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National...

Drugs and Medications [ 19 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [ 46 Associated PubMed Articles listed on BioPortfolio]

Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions.

Biotherapeutics, including recombinant or plasma-derived human proteins and antibody-based molecules, have emerged as an important class of pharmaceuticals. Aggregation and immunogenicity are among th...

Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration.

The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics. Key products on the biotherapeutic market such as insulins, but also several immunoglobulins or Fc-fusion...

Subcutaneous administration of biotherapeutics: Current experience in animal models.

In recent years, many peptide- and protein-based biotherapeutics have been approved for subcutaneous (SC) delivery. The mechanisms and factors affecting the uptake and distribution of such large molec...

Protein Particulate Detection Issues in Biotherapeutics Development-Current Status.

Formation of aggregates and particulates in biopharmaceutical formulation continues to be one of the major quality concerns in biotherapeutics development. The presence of large quantities of aggregat...

Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.

An immune response to a biotherapeutic can be induced when the therapeutic is processed and presented by antigen presenting cell to T helper cells. This study evaluates the performance of an in vitro...

Clinical Trials [ 15 Associated Clinical Trials listed on BioPortfolio]

Effects of a Lifestyle Intervention on Body Mass Index in Patients With Bipolar Disorder

Patients with bipolar disorder are at increased risk of weight gain, which in turn, increases the risk for somatic disease and non-adherence to maintenance therapy. Therefore, intervention...

Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.

This will be an open-label, single-dose, non-randomized, five-period crossover study in healthy volunteers. The duration of the study will last up to eleven weeks from screening to follow...

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

This is a multicentre study in which women were planned to receive either the HPV vaccine or control. Study participation will last approximately 48 months and involves a total of eleven s...

Use of a Mesh to Prevent Parastomal Hernia

Randomized, controlled, prospective study of 54 patients receiving surgery for cancer of the lower third of the rectum with a permanent end colostomy. The aim of the study was to reduce pa...

Companies [ 85 Associated Companies listed on BioPortfolio]

Eleven Biotherapeutics

Eleven Biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human...

Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics creates novel and differentiated biotherapeutics: first-of-a-kind protein-based drugs with significantly improved physical, pharmaceutical, and therapeutic...

One Eleven Software

One Eleven Software, a division of One Eleven Corporation, is a leader in the development of software solutions for healthcare professionals. For the past 16 years, One Eleven has...

One Eleven Corporation

One Eleven Corporation is a leader in the development of digital solutions for healthcare professionals. For the past 16 years, One Eleven has proven that healthcare professionals...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent...